Altered peptide ligands of myelin basic protein (MBP87-99) conjugated to reduced mannan modulate immune responses in mice

Immunology

Volumn 128, Issue 4, 2009, Pages 521-533

  Katsara, Maria ^a,b   Yuriev, Elizabeth ^c   Ramsland, Paul A ^a   Tselios, Theodore ^b   Deraos, George ^b   Lourbopoulos, Athanasios ^d   Grigoriadis, Nikolaos ^d   Matsoukas, John ^b   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF PATRAS   (Greece)

^c MONASH UNIVERSITY   (Australia)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Altered peptide ligand; Autoimmunity; I As; Mutant analogue; Myelin basic protein

Indexed keywords

ANTIBODY; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNAN; MYELIN BASIC PROTEIN; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VALYLHISTIDYLPHENYLALANYLPHENYLALANYLALANYLASPARAGINYL ISOLEUCYLVALYLTHREONYLALANYLARGINYLTHREONYLPROLINE; VALYLHISTIDYLPHENYLALANYLPHENYLALANYLARGINYLASPARAGINYL ISOLEUCYLVALYLTHREONYLALANYLARGINYLTHREONYLPROLINE; VALYLHISTIDYLPHENYLALANYLPHENYLALANYLLYSYLASPARAGINYL ISOLEUCYLVALYLTHREONYLPROLYLARGINYLTHREONYLPROLINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG CONJUGATION; EMULSION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MOLECULAR MODEL; MOUSE; MULTIPLE SCLEROSIS; MUTATION; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; BYSTANDER EFFECT; CROSS REACTIONS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FREUND'S ADJUVANT; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LIGANDS; MANNANS; MICE; MICE, INBRED STRAINS; MODELS, MOLECULAR; MULTIPLE SCLEROSIS; MUTATION; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; TH1 CELLS; TH2 CELLS;

EID: 70449339864     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03137.x     Document Type: Article

References (57)

1. Katsara M, Matsoukas J, Deraos G, Apostolopoulos V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim Biophys Sin 2008 40 : 636 642.
2. Martin R, Howell MD, Jaraquemada D et al. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 1991 173 (1 19 24.
3. Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL. Multiple sclerosis: genomic rewards. J Neuroimmunol 2001 113 : 171 184.
4. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990 346 : 183 187.
5. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994 179 : 973 984.
6. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005 204 : 208 231.
7. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996 85 : 299 302.
8. Sakai K, Sinha AA, Mitchell DJ, Zamvil SS, Rothbard JB, McDevitt HO, Steinman L. Involvement of distinct murine T-cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. Proc Natl Acad Sci USA 1988 85 : 8608 8612.
9. Sakai K, Zamvil SS, Mitchell DJ, Lim M, Rothbard JB, Steinman L. Characterization of a major encephalitogenic T cell epitope in SJL-J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol 1988 19 : 21 32.
10. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J Exp Med 1994 180 : 2227 2237.
11. Katsara M, Yuriev E, Ramsland PA, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses. J Neuroimmunol 2008 200 : 77 89.
12. Katsara M, Yuriev E, Ramsland PA, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Mannosylation of mutated MBP(83-99) peptides diverts immune responses from Th1 to Th2. Mol Immunol 2008 45 : 3661 3670.
13. Brocke S, Gijbels K, Allegretta M et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996 379 : 343 346.
14. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995 37 : 424 435.
15. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, Shevach EM, Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994 180 : 1961 1966.
16. Gaur A, Boehme SA, Chalmers D et al. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J Neuroimmunol 1997 74 : 149 158.
17. Gauthier L, Smith KJ, Pyrdol J, Kalandadze A, Strominger JL, Wiley DC, Wucherpfennig KW. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc Natl Acad Sci USA 1998 95 : 11828 11833.
18. Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 2005 24 : 2968 2979.
19. Smith KJ, Pyrdol J, Gauthier L, Wiley DC, Wucherpfennig KW. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998 188 : 1511 1520. (Pubitemid 28489588)
20. Wucherpfennig KW, Hafler DA, Strominger JL. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2-peptide complexes. Proc Natl Acad Sci USA 1995 92 : 8896 8900.
21. Kalbus M, Fleckenstein BT, Offenhausser M et al. Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-A(s). Eur J Immunol 2001 31 : 551 562.
22. Matsoukas J, Apostolopoulos V, Kalbacher H et al. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J Med Chem 2005 48 : 1470 1480.
23. Katsara M, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL-J mice. J Med Chem 2008 51 : 3971 3978.
24. Katsara M, Tselios T, Deraos S, Deraos G, Matsoukas MT, Lazoura E, Matsoukas J, Apostolopoulos V. Round and round we go: cyclic peptides in disease. Curr Med Chem 2006 13 : 2221 2232.
25. Acres B, Apostolopoulos V, Balloul JM et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 2000 48 : 588 594.
26. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 2000 18 : 3174 3184.
27. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 1997 159 : 5211 5218.
28. Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr Mol Med 2001 1 : 469 474.
29. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 2000 30 : 1714 1723.
30. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative-reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995 92 : 10128 10132.
31. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996 14 : 930 938.
32. Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006 118 : 372 383.
33. Tselios T, Apostolopoulos V, Daliani I et al. Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J Med Chem 2002 45 : 275 283.
34. Tselios T, Daliani I, Deraos S et al. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. Bioorg Med Chem Lett 2000 10 : 2713 2717.
35. Tselios T, Daliani I, Probert L et al. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides. Bioorg Med Chem 2000 8 : 1903 1909.
36. Tselios T, Probert L, Daliani I et al. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J Med Chem 1999 42 : 1170 1177.
37. Tselios TV, Lamari FN, Karathanasopoulou I, Katsara M, Apostolopoulos V, Pietersz GA, Matsoukas JM, Karamanos NK. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Anal Biochem 2005 347 : 121 128.
38. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995 8 : 127 134.
39. Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 2003 100 : 15029 15034.
40. de Graaf KL, Weissert R, Kjellen P, Holmdahl R, Olsson T. Allelic variations in rat MHC class II binding of myelin basic protein peptides correlate with encephalitogenicity. Int Immunol 1999 11 : 1981 1988.
41. Stepaniak JA, Gould KE, Sun D, Swanborg RH. A comparative study of experimental autoimmune encephalomyelitis in Lewis and DA rats. J Immunol 1995 155 : 2762 2769.
42. Weissert R, Lobell A, de Graaf KL, Eltayeb SY, Andersson R, Olsson T, Wigzell H. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proc Natl Acad Sci USA 2000 97 : 1689 1694.
43. Harding CV, Leyva-Cobian F, Unanue ER. Mechanisms of antigen processing. Immunol Rev 1988 106 : 77 92.
44. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991 252 : 1308 1310.
45. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol 1993 1 (Pt 1) : 3131 3140.
46. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993 363 : 156 159.
47. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995 3 : 397 405.
48. Windhagen A, Scholz C, Hollsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995 2 : 373 380.
49. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991 5 : 171 177.
50. Swain SL. IL4 dictates T-cell differentiation. Res Immunol 1993 144 : 616 620.
51. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med 2000 6 : 1167 1175.
52. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nature Med 2000 6 : 1176 1182.
53. Iero M, Squarcina P, Romero P et al. Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother 2007 56 : 1979 1991.
54. Pietersz GA, Li W, Popovski V, Caruana JA, Apostolopoulos V, McKenzie IF. Parameters for using mannan-MUC1 fusion protein to induce cellular immunity. Cancer Immunol Immunother 1998 45 : 321 326.
55. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA. A functional hot spot for antigen recognition in a superagonist TCR-MHC complex. Immunity 2000 12 : 251 261.
56. Thomson CT, Kalergis AM, Sacchettini JC, Nathenson SG. A structural difference limited to one residue of the antigenic peptide can profoundly alter the biological outcome of the TCR-peptide-MHC class I interaction. J Immunol 2001 166 : 3994 3997.
57. Kalergis AM, Nathenson SG. Altered peptide ligand-mediated TCR antagonism can be modulated by a change in a single amino acid residue within the CDR3 beta of an MHC class I-restricted TCR. J Immunol 2000 165 : 280 285.